Preclinical models demonstrated that highly selective MEK inhibitors inhibited tumor progress and promoted changes in the proliferation and effector phenotype of CD8+ TILs (55).This showed that the MEK inhibitors combined with ICIs treatment may synergistically inhibit tumor growth. Here, CD8A is linked to neoplasm.